ArticleBMC endocrine disorders2025
Clinical characteristics and outcomes in patients with diabetes mellitus affected by COVID-19: a retrospective cross-sectional study from a tertiary care center in Pakistan.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical outcomes and predictive modeling in COVID-19 patients with type 2 diabetes mellitus: a multicenter retrospective cohort study.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19, caused by SARS-CoV-2, emerged in December 2019 and quickly became a global public health concern. Diabetes, a major risk factor for severe COVID-19, affects 537 million people worldwide, with high prevalence in low- and middle-income countries like Pakistan. Studies show diabetes increases the risk of severe COVID-19 complications and mortality. However, there is limited data on COVID-19 outcomes in diabetic patients in Pakistan. This study aims to fill this gap and examine factors affecting outcomes in this population.
methodsWe conducted a retrospective cross-sectional study at The Aga Khan University Hospital, Karachi, encompassing 2,346 confirmed COVID-19 patients from February 26, 2020, to September 6, 2021. Data on diabetic status, following ADA guidelines and other clinical outcomes were collected from medical records and patient interviews. Statistical analysis was performed using SPSS V.25.
resultsA total of 1,342 patients were included, with 864 males (64.4%) and 478 females (35.6%). The mean age was 56.59 ± 15.55 years. SARS-CoV-2 infection was the primary diagnosis for 741 patients (55.2%), while 601 patients (44.8%) had it as a secondary diagnosis. Of the total, 348 patients (25.9%) had T2DM, 2 patients (0.15%) had T1DM, and 991 patients (73.8%) were non-diabetic. The mean duration of diabetes was 2.01 ± 1.32 years. Diabetic patients had a significantly shorter mean hospital stay (4.99 ± 4.46 days) compared to non-diabetic patients (6.79 ± 7.32 days) (p < 0.001). The overall discharge rate was 70.3%, with a mortality rate of 10.7%. T2DM was associated with lower in-hospital mortality (p < 0.001) but higher rates of ARDS (p < 0.001). There was no significant association between T2DM and the risk of pulmonary aspergillosis, pulmonary embolism, or septic shock. Higher financial class was associated with longer hospital stays and a greater likelihood of being discharged home (p < 0.001).
conclusionIn conclusion, our study highlights the heightened susceptibility of COVID-19 patients with concurrent T1DM and T2DM to developing ARDS. Despite no significant association found between diabetes and adverse outcomes, the crucial role of tailored care for high-risk groups, particularly those with diabetes, cannot be overstated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.